NCT01300156

Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgkin's Lymphoma (HL)

A Multicenter Phase II Study of Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Patients With Refractory or Relapsed Hodgkin's Lymphoma (HL)

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (estimated)
• Sponsor: National Cancer Center, Korea · Other Government
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of combination chemotherapy with etoposide, methylprednisolone, high-dose cytarabine and oxaliplatin (ESHAOx) for patients with refractory or relapsed Hodgkin's lymphoma (HL).

Conditions

• Hodgkin's Lymphoma

Interventions

Type	Name	Description
DRUG	Oxaliplatin-based chemotherapy (ESHAOx)	* Etoposide 40 mg/m2, D1-4 * Methylprednisolone 500mg, D1-5 * Cytarabine 2 g/m2, D5 * Oxaliplatin 130 mg/m2, D1

Timeline

• Start date: 2011-02-01
• Primary completion: 2013-06-01
• Completion: 2013-12-01
• First posted: 2011-02-21
• Last updated: 2011-02-21

Locations

1 site across 1 country: South Korea